Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02073682 · ClinicalTrials.gov registry record · Phase 3
Cancer Venous Thromboembolism (VTE)
A Phase 3 study of Cancer and Deep Vein Thrombosis (DVT), sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,046
- Enrollment target
- 9
- Study locations
NCT02073682: Completed Phase 3 study of Cancer and Deep Vein Thrombosis (DVT), sponsored by Daiichi Sankyo.
NCT02073682 is a Phase 3 study of Cancer and Deep Vein Thrombosis (DVT) that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,046 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (70% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02073682, a Phase 3 study of Cancer and Deep Vein Thrombosis (DVT), has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,046 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.
Conditions Studied
Interventions
- DRUG Edoxaban
- DRUG Dalteparin
- DRUG Low molecular weight heparin
Study Locations (9)
Other
- - Saint-Etienne
- - Varese
- - Amsterdam
Florida
- - Brandon
Georgia
- - Jonesboro
Michigan
- - Detroit
Virginia
- - Norfolk
Vlaams-Brabant
- - Leuven
Hajdu-Bihar Megye
- - Debrecen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2015-07-16 |
| Est. Completion | 2017-09-15 |
| Phase | Phase 3 |
What the finished NCT02073682 record still lists
NCT02073682 is an interventional study that assigns participants to a tested intervention. Its 1,046 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (70% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Edoxaban is the first listed.
NCT02073682 lists 9 locations in 7 states (Other, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT02073682 about?
NCT02073682 is a clinical study titled "Cancer Venous Thromboembolism (VTE)". The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month s...
What is the current status of trial NCT02073682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,046 participants. The study started on 2015-07-16. Estimated completion is 2017-09-15.
What conditions does trial NCT02073682 study?
This clinical trial studies the following conditions: Cancer, Deep Vein Thrombosis (DVT), Venous Thromboembolism (VTE), Pulmonary Embolism (PE).
What interventions are being tested in trial NCT02073682?
The interventions under investigation include: Edoxaban (DRUG), Dalteparin (DRUG), Low molecular weight heparin (DRUG).
Who is sponsoring clinical trial NCT02073682?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02073682 being conducted?
This trial has 9 study locations across Florida, Georgia, Michigan, Virginia, Vlaams-Brabant. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02073682's enrollment target sits among peer trials
1,046 77th of 615 higher than 539 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI